Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura

Blood

Volumn 128, Issue 17, 2016, Pages 2175-2178

  Page, Evaren E ^a,b   Kremer Hovinga, Johanna A ^c,d   Terrell, Deirdra R ^a   Vesely, Sara K ^a   George, James N ^a,b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAMTS13 PROTEIN, HUMAN; AUTOANTIBODY; BIOLOGICAL MARKER;

ENZYME ACTIVITY; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; LETTER; MAINTENANCE THERAPY; PRIORITY JOURNAL; RELAPSE; REMISSION; THROMBOTIC THROMBOCYTOPENIC PURPURA; BLOOD; COHORT ANALYSIS; IMMUNOLOGY; METABOLISM; PREDICTIVE VALUE; PROGNOSIS; RECURRENT DISEASE;

ADAMTS13 PROTEIN; AUTOANTIBODIES; BIOMARKERS; COHORT STUDIES; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; REMISSION, SPONTANEOUS;

EID: 84994045323     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-06-724161     Document Type: Letter

References (16)

1. Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115(8):1500-1511, quiz 1662.
2. Ferrari S, Palavra. K, Gruber B, Kremer Hovinga JA, Knöbl P, Caron C, Cromwell C, Aledort L, Plaimauer B, Turecek PL, Rottensteiner H, Scheiflinger F. Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura. Haematologia. 2014;99(4):779-787.
3. Hie M, Gay J, Galicier L, et al; French Thrombotic Microangiopathies Reference Centre. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood. 2014;124(2):204-210.
4. Jin M, Casper TC, Cataland SR, et al. Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol. 2008;141(5):651-658.
5. Peyvandi F, Lavoretano S, Palla R, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica. 2008;93(2):232-239.
6. Westwood JP, Webster H, McGuckin S, McDonald V, Machin SJ, Scully M. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost. 2013;11(3):481-490.
7. Lim W, Vesely SK, George JN. The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood. 2015;125(10):1526-1531.
8. Vesely SK, George JN, Lämmle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102(1):60-68.
9. Allison PD. Survival Analysis Using SAS: A Practical Guide. 2nd ed. Cary, NC: SAS Institutes; 2010.
10. Deford CC, Reese JA, Schwartz LH, et al. Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood. 2013;122(12):2023-2029, quiz 2142.
11. Han B, Page EE, Stewart LM, et al. Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. Am J Hematol. 2015;90(8):709-714.
12. Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol. 2001;14(2):437-454.
13. Fujimura Y, Matsumoto M, Isonishi A, et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost. 2011;9(suppl 1):283-301.
14. Fuchs TA, Kremer Hovinga JA, Schatzberg D, Wagner DD, Lämmle B. Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood. 2012;120(6):1157-1164.
15. Miyata T, Fan X. A second hit for TMA. Blood. 2012;120(6):1152-1154.
16. Pillai VG, Bao J, Zander CB, et al. Human neutrophil peptides inhibit cleavage of von Willebrand factor by ADAMTS13: a potential link of inflammation to TTP. Blood. 2016;128(1):110-119.